BPC-157 TB-500 is a two-peptide research blend studied for tissue repair, presented here with its safety record kept in view.

Two specimens, one repair rationale

BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair blend — marketed and discussed as the "Wolverine" stack — that pairs BPC-157 with TB-500. It is not a single chemical entity. It has no molecular weight, CAS number, or approved indication of its own; the values below describe its two constituents ^[1][3]. This site reads the blend the way a studio reads a product: each peptide set down on its own plinth, shown accurately, with the gaps and the one flagged safety signal left in plain light.

The first specimen is BPC-157 (Body Protection Compound 157), a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a protein found in human gastric juice. In rodent tissue-repair models it accelerated healing of a fully transected Achilles tendon across biomechanical, functional, and microscopic measures at 10 microg/kg ^[1], and it is pro-angiogenic by up-regulating VEGFR2 with downstream Akt-eNOS signaling ^[2].

The second specimen is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, ~889.0 Da) corresponding to the actin-binding region — residues 17-23 — of the 43-residue protein Thymosin Beta-4. Its LKKTETQ motif binds monomeric G-actin in a 1:1 complex and sequesters it, regulating the cytoskeletal dynamics that drive cell migration ^[3][4]. One caveat carries through everything that follows: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer ^[4][7]. The honest reading of each leg, and the missing combination evidence, runs through BPC-157 vs TB-500 mechanisms.

BPC-157 and TB-500: the two peptides in the Wolverine blend

BPC-157 and TB-500 are paired because each addresses a different node of tissue repair, and the blend's whole identity rests on that division of labor. The pairing is best read one specimen at a time before any claim about the two together ^[2][3].

BPC-157 holds the cytoprotective and pro-angiogenic node — VEGFR2-Akt-eNOS angiogenesis, nitric-oxide modulation, and growth-hormone-receptor-driven fibroblast proliferation ^[2]. TB-500 holds the cytoskeletal node — 1:1 G-actin sequestration via the LKKTETQ motif, regulating the cell migration and re-epithelialization that resurface a wound ^[3][4]. The two are described as acting through complementary but largely non-overlapping pathways, which is the basis of the "synergy" claim and the reason researchers pair them. That rationale is unpacked, with its missing evidence, on the combination-rationale and synergy claim.

What is the Wolverine peptide blend?

The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product; it carries no single molecular weight or CAS number ^[1][3]. The search term's volume is heavily conflated with the comic-book character — this site is the peptide-blend reading, not the fictional one.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region, residues 17-23, of Thymosin Beta-4 ^[1][3]. The blend combines the two as a tissue-repair stack; it is not a single molecule or an approved product.

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid gastric-juice-derived cytoprotective and pro-angiogenic peptide; TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting on cytoskeletal migration ^[1][3]. Different sequences, different molecular weights, different mechanisms — which is why they are presented as two distinct specimens rather than one substance.

The BPC-157 TB-500 stack: what it is and what it is not

The BPC-157 TB-500 stack assembles two separately characterized repair signals into one vial. On the evidence, the two halves differ in maturity but match in one respect: neither has been tested as part of the blend ^[8][9].

BPC-157's record is the more developed. A 2025 systematic review of BPC-157 in orthopaedic sports medicine catalogued 36 studies — 35 preclinical, exactly one human — found "no clinical safety data," and rated the evidence at the lowest tiers, level IV-V ^[8]. A 2025 narrative review reached the same reading: broad preclinical support, only three small human pilot studies, and a recommendation to treat BPC-157 as investigational given regulatory controversy and non-regulated availability ^[10].

TB-500's record leans on its parent protein. Thymosin Beta-4 binds actin, promotes cell migration, reduces myofibroblast number, and promotes angiogenesis ^[4]; the synthetic heptapeptide sold as TB-500 was characterized as the Ac-17-23 fragment for doping-control reference ^[7], but the bulk of the efficacy data was generated with the full-length protein. The assembled product sits on top of both records without adding to either: no peer-reviewed study has tested the combined BPC-157 plus TB-500 blend for any indication ^[8]. The 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides lists both compounds, notes favorable animal-model outcomes, and cautions that rigorous human safety data are scarce, with potential for serious harm ^[9]. The honest-risk reading is laid out in BPC-157 TB-500 side effects and safety research, and the studied research doses sit on studied research doses (animal models).

How this brief reads the blend

The discipline of this site is to read each specimen against its own studies and to refuse to let a claim about the two together borrow credibility from either alone. A finding from BPC-157 is a BPC-157 finding; a finding from Thymosin Beta-4 is a Thymosin Beta-4 finding; and a claim about the combination is, at present, an empty entry on the record ^[8].

That discipline matters most where safety is concerned. The principal theoretical concern is a pro-angiogenic, pro-migratory tumor signal associated with Thymosin Beta-4 — the same properties that aid repair could, in theory, support tumor progression, and that is the kind of signal that compounds rather than cancels when two pro-repair peptides are combined ^[4]. The full reading sits at the Thymosin Beta-4 tumor/angiogenesis safety signal.

The pages ahead present the record straight: the mechanism literature on BPC-157 vs TB-500 mechanisms, the honest safety reading on BPC-157 TB-500 side effects and safety research, the animal-model dose context on studied research doses (animal models), the present-tense regulatory picture on Wolverine legal status and 503A compounding, the frequently asked questions about the blend, and the full reference list.